AstraZeneca has reportedly held talks with Bristol Myers Squibb regarding a potential $400 billion merger, raising eyebrows among analysts and investors. While the idea of a megadeal between these pharma giants could create a leading force in the cancer drug market, many stakeholders question the logic and potential complications of such a move. Following the news, AstraZeneca shares fell approximately 8.9%, leading to concerns about the viability and strategy behind this merger proposal. Meanwhile, Bristol Myers Squibb’s stock saw an increase amid the speculation. The discussions have left investors baffled, with several experts cautioning that the merger could bring more challenges than benefits.